Quick Answer
Allarity Therapeutics, Inc. reported Net Income of -$11.23 million for fiscal year 2025.
Allarity Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$11.23M | +54.2% |
| 2024 | -$24.52M | -106.0% |
| 2023 | -$11.90M | +25.9% |
| 2022 | -$16.06M | +39.7% |
| 2021 | -$26.65M | -302.7% |
| 2020 | -$6.62M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.81M | +75.8% | -20.9% |
| June 30, 2025 | -$2.32M | -42.4% | +15.1% |
| March 31, 2025 | -$2.73M | +28.9% | +76.4% |
| September 30, 2024 | -$11.59M | -160.6% | -611.5% |
| June 30, 2024 | -$1.63M | +31.6% | +57.6% |
| March 31, 2024 | -$3.84M | -14.6% | +13.6% |
| September 30, 2023 | -$4.45M | +11.7% | -86.8% |
| June 30, 2023 | -$2.38M | +53.4% | +29.0% |
- Allarity Therapeutics, Inc. showed an increase of +54.2% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Allarity Therapeutics, Inc.’s net income has declined by 69.7% (from -$6.62 million to -$11.23 million).
- The most recent figure is from Allarity Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: